Ustekinumab (anti-IL-12/IL-23)

Synonyms: CNTO 1275

Catalog No.A2024 Purity: 99.12%

Ustekinumab (CNTO 1275) is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody used to treat psoriasis. MW=145.6 kDa.

Click to purchase the isotype control of Ustekinumab (anti-IL-12/IL-23)

Purity & Quality Control

Batch: A202401 Purity: 99.12% Protein concentration: 5.00mg/ml Endotoxin Level: ≤1 EU/mg

99.12

Choose Selective Interleukins Inhibitors

Biological Activity

Description	Ustekinumab (CNTO 1275) is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody used to treat psoriasis. MW=145.6 kDa.

In Vitro
In vitro	The addition of Ustekinumab (UST) significantly inhibits T follicular helper (TFH) cell differentiation in vitro.^[1]
Cell Research:	Objective: TFH cell differentiation assay Cells: naïve CD4+ T cells, T follicular helper (TFH) cells, PBMCs Concentrations: 100 ng/mL Incubation Time: 24 h Method: The TFH cell differentiation assay is performed with freshly isolated PBMCs from healthy donors (n = 16). Naïve CD4+ T cells are isolated by using the human Naïve CD4+ T Cell Isolation Kit II. A total of 500,000 naïve CD4+ T cells are cultured in complete medium in the presence of 12.5 μL/mL anti-CD3/CD28 in a flat-bottom 48 well plate. After 24 hours of culture, cytokines are added and cells are incubated for additional 2.5 days. A total of 5 ng/mL IL-12 + 5 ng/mL TGFβ with and without 100 ng/mL UST and 100 ng/mL UST alone are used. Reference: https://pubmed.ncbi.nlm.nih.gov/32679193 Ustekinumab can apply to humanized mice, peripheral blood and other related assays (Only for Reference)

In Vitro

In vitro

The addition of Ustekinumab (UST) significantly inhibits T follicular helper (TFH) cell differentiation in vitro.^[1]

Cell Research:

Objective: TFH cell differentiation assay
Cells: naïve CD4+ T cells, T follicular helper (TFH) cells, PBMCs
Concentrations: 100 ng/mL
Incubation Time: 24 h
Method: The TFH cell differentiation assay is performed with freshly isolated PBMCs from healthy donors (n = 16). Naïve CD4+ T cells are isolated by using the human Naïve CD4+ T Cell Isolation Kit II. A total of 500,000 naïve CD4+ T cells are cultured in complete medium in the presence of 12.5 μL/mL anti-CD3/CD28 in a flat-bottom 48 well plate. After 24 hours of culture, cytokines are added and cells are incubated for additional 2.5 days. A total of 5 ng/mL IL-12 + 5 ng/mL TGFβ with and without 100 ng/mL UST and 100 ng/mL UST alone are used.
Reference: https://pubmed.ncbi.nlm.nih.gov/32679193

Ustekinumab can apply to humanized mice, peripheral blood and other related assays (Only for Reference)

In Vivo
In vivo	Ustekinumab is generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. Ustekinumab binds to the p40 subunit common to IL-12 and IL-23 and prevents their interaction with the IL-12 receptor β1 subunit of the IL-12 and IL-23 receptor complexes.^[2]

References
[1] Anna-Maria Globig, et al. Cell Mol Gastroenterol Hepatol. 2021;11(1):1-12. [2] Jacqueline M Benson, et al. MAbs. Nov-Dec 2011;3(6):535-45.

References

Product Details

CAS No.	815610-63-0
Isotype	Human IgG1
Source	Human
Formulation	PBS, PH7.2
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field